(Total Views: 555)
Posted On: 03/30/2022 2:26:30 PM
Post# of 154875
I agree that more than one item should be on the agenda. Not that it is of much import but the following are my priorities:
1. Finances. We must be running on fumes. But if you believe in the science, the biggest hold back is financing operations. Of course partnership or buyout could provide the answer. I can see a buyout or partnership offer including both cash and stock!
2. HIV BLA I bought when the indications for HIV were coming up strong. Submission of our BLA to FDA would indicate that Dr Recknor got usable data from Amarex and kept to the last estimate of analysis and completion.
3. NASH 700 data. We seemed so close in January, I have to believe we have smashing stats for NASH efficacy.
4. New CEO. Unless it is Jimmy Merck or Susie Pfizer, I don’t need to listen to that announcement at 5:30 am.
5. COVID update for Brazil. I am of the opinion that our very meager enrollment is a function of lack of funds to pay for the whole trial in Brazil. That may now be changing.
6. Interest in our company from other sources. Obviously this would include partnership or buyout but could also include DARPA and other government or NGOs
7. Any news on the international front from Britain, Canada or other sources.
Just my own list. I hope I wake up early!
1. Finances. We must be running on fumes. But if you believe in the science, the biggest hold back is financing operations. Of course partnership or buyout could provide the answer. I can see a buyout or partnership offer including both cash and stock!
2. HIV BLA I bought when the indications for HIV were coming up strong. Submission of our BLA to FDA would indicate that Dr Recknor got usable data from Amarex and kept to the last estimate of analysis and completion.
3. NASH 700 data. We seemed so close in January, I have to believe we have smashing stats for NASH efficacy.
4. New CEO. Unless it is Jimmy Merck or Susie Pfizer, I don’t need to listen to that announcement at 5:30 am.
5. COVID update for Brazil. I am of the opinion that our very meager enrollment is a function of lack of funds to pay for the whole trial in Brazil. That may now be changing.
6. Interest in our company from other sources. Obviously this would include partnership or buyout but could also include DARPA and other government or NGOs
7. Any news on the international front from Britain, Canada or other sources.
Just my own list. I hope I wake up early!
(4)
(0)
